Published Research

  1. Bingham JM, Black M, Anderson EJ, Li Y, Toselli N, Fox S, Martin JR, Axon DR, and Silva-Almodóvar A. Impact of Telehealth Interventions on Medication Adherence for Patients With Type 2 Diabetes, Hypertension, and/or Dyslipidemia: A Systematic Review. Annals of Pharmacotherapy. 20 August 2020.
  2. Ballinghoff T, Bain K, Matos A, Bardolia C, Turgeon J, and Amin N. Opioid Response in an Individual with Altered CYP2D6 Activity: Implications of a Pharmacogenomics Case. Authorea. 06 August 2020.
  3. Gabbay RA, Kendall D, Beebe C, Cuddeback J, Hobbs T, Khan ND, Leal S, Miller E, Novak LM, Rajpathak SN, Scribner P, Meneghini L, and Khunti K. Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. Perspectives in Clinial Diabetes. 31 July 2020.
  4. Bingham JM, Almodovar AS, Taylor AM, Azon DR, Nahata MC, Leal S, Warholak T, and Scovis N. A Research Partnership to Enhance Postgraduate Pharmacy Residency Training Outcomes. Pharmacy. 31 July 2020.
  5. Michaud V, Dow P, Al Rihani S, Deodhar M, Arwood M, Cicali B, and Turgeon J. Risk assessment of drug‐induced Long QT Syndrome for some COVID‐19 repurposed drugs. Clinical and Translational Science. doi:10.1111/cts.12882. 05 September 2020
  6. Campbell PJ, Axon DR, Taylor AM, Pickering M, Black H, Warholak T, and Chinthammit C. Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study. Journal of the American Heart Association. 26 Aug 2020.
  7. Al Rihani SB, Smith MK, Bikmetov R, Deodhar M, Dow P, Turgeon J, and Michaud V. Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy. J. Clin. Med. 2020, 9(8), 2591.
  8. Bankes D, Jin H, Finnel S, Michaud V, Knowlton CH, Turgeon J, and Stein A. Association of a Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Elderly. Pharmacy 2020, 8(2), 87.
  9. Turgeon J, Michaud V. Clinical Decisions Support Systems: Great Promises for Better Management of Patients’ Drug Therapy. Expert Opin Drug Metab Toxicol 2016;12(9):993-995.
  10. Deodhar M, Al Rihani S, Arwood MJ, Darakjian L,Dow P, Turgeon J, and Michaud V.
    Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics 2020, 12(9), 846.
  11. Matos A, Bankes DL, Bain KT, Ballinghoff T, and Turgeon J. Opioids, Polypharmacy, and Drug Interactions: A Technological Paradigm Shift Is Needed to Ameliorate the Ongoing Opioid Epidemic. Pharmacy 2020, 8(3), 154.
  12. Bain KT, Knowlton C, Matos A. Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly. Pharmacogenomics, 9 Jun 2020.
  13. Cicali B, Michaud V, Knowlton C, Turgeon J. Application of a Novel Medication-Related Risk Stratification Strategy to a Self-Funded Employer’s Population. Benefits Quarterly. Q2 2018.
  14. Bain KT, Schwartz EJ, Knowlton OV, Knowlton CH, Turgeon J. Implementation of a Pharmacist-Led Pharmacogenomics Service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE). J Am Pharm Assoc 2018;58(3):281-289.
  15. Schwartz EJ, Turgeon J, Patel J, Patel P, Shah H, Issa AM, Knowlton OV, Knowlton CH, Bain KT. Implementation of a Standardized Medication Therapy Management Plus Approach within Primary Care. J Am Board Fam Med 2017;30(6):701-714.
  16. Bain KT, Knowlton CH, Turgeon J. Medication Risk Mitigation: Coordinating and Collaborating with Health Care Systems, Universities, and Researchers to Facilitate the Design and Execution of Practice-Based Research. Clin Geriatr Med 2017;33(2):257-281.
  17. Turgeon J, Michaud V, Steffen L. The Dangers of Polypharmacy in Elderly Patients. JAMA Intern Med 2017;177(10):1544.
  18. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and Risk of Potential Cytochrome P450-Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy. Ann Pharmacother 2013;47(3):324-332.
  19. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and Risk of Potential Cytochrome P450-Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy. Ann Pharmacother 2013;47(3):324-332.
  20. Caillier B, Pilote S, Castonguay A, et al. QRS Widening and QT Prolongation under Bupropion: a Unique Cardiac Electrophysiological Profile. Fundam Clin Pharmacol 2012;26(5):599-608.
  21. Plante I, Vigneault P, Drolet B, Turgeon J. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci 2012;101(2):868-878.
  22. Bain KT. Anticholinergic Burden: Tracking Adverse Effects. Aging Well. 2011;4(2):8-11.
  23. Zakrzewski-Jakubiak H, Doan J, Lamoureux P, Singh D, Turgeon J, Tannenbaum C. Detection and Prevention of Drug-Drug Interactions in the Hospitalized Elderly: Utility of New Cytochrome P450-Based Software. Am J Geriatr Pharmacother 2011;9(6):461-470.
  24. Hreiche R, Morissette P, Turgeon J. Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend Med 2008;5(2):124-135.
  25. Bain KT, Holmes HM, Beers MH, Maio V, Handler SM, Pauker SG. Discontinuing Medications: A Novel Approach for Revising the Prescribing Stage of the Medication-Use Process. J Am Geriatr Soc 2008;56(10):1946-1952.
  26. Bain KT. Adverse Drug Reactions and Current State of Drug Regimen Review in Nursing Facilities: Need for a Change? Consult Pharm 2007;22(7):586-592.
  27. Bain KT, Weschules DJ, Tillotson P. Prevalence and Predictors of Medication-related Problems. Medicare Patient Management 2006;1(1):14-27.